256 related articles for article (PubMed ID: 24887392)
1. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
[TBL] [Abstract][Full Text] [Related]
2. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
3. Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer.
Finelli A; Komisarenko M; Martin LJ; Timilshina N; Jain K; Morris J; Zlotta A; Kulkarni G; Perlis N; van der Kwast T; Evans A; Ghai S; Fleshner N; Alibhai SMH; Hamilton RJ
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):69-76. PubMed ID: 32152437
[TBL] [Abstract][Full Text] [Related]
4. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
5. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
Bonde Miranda T; Garmo H; Stattin P; Robinson D
J Urol; 2020 Oct; 204(4):714-719. PubMed ID: 32243243
[TBL] [Abstract][Full Text] [Related]
6. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
7. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort.
Dekalo S; McArthur E; Campbell J; Ordon M; Power N; Welk B
Urol Oncol; 2023 Jan; 41(1):50.e11-50.e17. PubMed ID: 36319553
[TBL] [Abstract][Full Text] [Related]
8. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
[TBL] [Abstract][Full Text] [Related]
9. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR
Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197
[TBL] [Abstract][Full Text] [Related]
10. Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy.
Heo JE; Koo KC; Hong SJ; Park SU; Chung BH; Lee KS
Yonsei Med J; 2018 Mar; 59(2):219-225. PubMed ID: 29436189
[TBL] [Abstract][Full Text] [Related]
11. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
[TBL] [Abstract][Full Text] [Related]
13. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
14. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology.
Bird ST; Delaney JA; Brophy JM; Etminan M; Skeldon SC; Hartzema AG
BMJ; 2013 Nov; 347():f6320. PubMed ID: 24192967
[TBL] [Abstract][Full Text] [Related]
15. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
16. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.
Thakrar DB; Douglas IJ; Smeeth L; Bhaskaran K
Wellcome Open Res; 2023; 8():295. PubMed ID: 38774490
[No Abstract] [Full Text] [Related]
17. Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.
Scailteux LM; Rioux-Leclercq N; Vincendeau S; Balusson F; Nowak E; Oger E;
BJU Int; 2019 Feb; 123(2):293-299. PubMed ID: 30025199
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
19. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
[TBL] [Abstract][Full Text] [Related]
20. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]